<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04260659</url>
  </required_header>
  <id_info>
    <org_study_id>OFA LSG</org_study_id>
    <nct_id>NCT04260659</nct_id>
  </id_info>
  <brief_title>Opioid Free vs Opioid Based Anesthesia for Laparoscopic Sleeve Gastrectomy</brief_title>
  <official_title>Opioid Free vs Opioid Based Anesthesia for Laparoscopic Sleeve Gastrectomy: Clinical, Randomised Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Warsaw</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Opioid free anesthesia is an anesthetic technique, in which administration of multimodal
      analgesia and sympathicolytics provides hemodynamic stability without use of opioids. Such
      management may be beneficial to the obese patients undergoing laparoscopic sleeve
      gastrectomy. Our study aims to compare opioid free anesthesia in such patients with standard,
      short-acting opioid based.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study has been approved by Bioethical Committee of Medical University of Warsaw. Informed
      written consent will be obtained from all patients. Sample size of 60 patients has been
      calculated based on the Altman normogram to obtain 30% reduction of postoperative opioid
      consumption with significance and power of 90%.

      Consenting patients scheduled for laparoscopic sleeve gastrectomy will be randomly assigned
      to the computer generated list to receive opioid free or standard opioid based anesthesia.

      Opioid free protocol includes administration of dexmedetomidine, lidocaine, ketamine,
      magnesium sulphate whereas standard group will receive remifentanil TCI Minto Model.

      After the end of operation all of the patient will receive oxycodone and additional doses via
      PCA system for postoperative analgesia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2020</start_date>
  <completion_date type="Anticipated">February 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 4, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total postoperative oxycodone consumption</measure>
    <time_frame>Day &quot;0&quot;</time_frame>
    <description>PCA (Patient's controlled analgesia) iv pump, oxycodone will be administered on patient's demand by 2mg boli, with lock out time 10 minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative pain score in NRS scale</measure>
    <time_frame>Day &quot;0&quot;, assessed 1 hour after operation</time_frame>
    <description>NRS range from 0 for no pain to 10 for worst pain imaginable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative pain score in NRS scale</measure>
    <time_frame>Day &quot;0&quot;, assessed 6 hours after operation</time_frame>
    <description>NRS range from 0 for no pain to 10 for worst pain imaginable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative pain score in NRS scale</measure>
    <time_frame>Day &quot;0&quot;, assessed 12 hours after operation</time_frame>
    <description>NRS range from 0 for no pain to 10 for worst pain imaginable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative pain score in NRS scale</measure>
    <time_frame>Day &quot;1&quot; assessed 24 hours after operation</time_frame>
    <description>NRS range from 0 for no pain to 10 for worst pain imaginable</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative sedation score</measure>
    <time_frame>Day &quot;0&quot;, assessed 1,6,12 and 24 hours after operation</time_frame>
    <description>1-6 Ramsay sedation score; 1 - agitated or restless 6 - unresponsive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative nausea and vomiting</measure>
    <time_frame>Day &quot;0&quot;, assessed 1,6,12 and 24 hours after operation</time_frame>
    <description>Simplified PONV impact scale 0-6 0 - no nausea nor vomiting 6 - &gt;3 episodes of vomiting and nausea all of the time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue fentanyl administration dosis</measure>
    <time_frame>intraoperative</time_frame>
    <description>In opioid free group, rescue fentanyl dosis will be administered if hypertension &gt; 140/90 mmHg or tachycardia &gt; 120/min occurs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Highest BP</measure>
    <time_frame>intraoperative</time_frame>
    <description>Highest BP during operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lowest BP</measure>
    <time_frame>intraoperative</time_frame>
    <description>Lowest BP during operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Highest HR</measure>
    <time_frame>intraoperative</time_frame>
    <description>Highest HR during operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lowest HR</measure>
    <time_frame>intraoperative</time_frame>
    <description>Lowest HR during operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total ephedrine dosis</measure>
    <time_frame>intraoperative</time_frame>
    <description>Ephedrine is a vasopressor used in case of hypotension to maintain mean arterial pressure &gt; 65 mmHg or to increase blood pressure to check surgical hemostasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative desaturation</measure>
    <time_frame>Day &quot;0&quot;, assessed 1,6,12 and 24 hours after operation</time_frame>
    <description>SpO2 &lt; 94%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's comfort assessed in QoR-40 formulary</measure>
    <time_frame>7 days postoperatively</time_frame>
    <description>QoR-40 scale is used to measure the quality of recovery after surgery and anesthesia, it is a 40 item questionnaire that provides a score across five dimensions: patient support, comfort, emotions, physical independence, and pain. Formulary will assess first 24 hours following the operation and will be filled by the patient 7 days after operation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obesity</condition>
  <condition>Postoperative Pain</condition>
  <condition>Postoperative Nausea</condition>
  <condition>Postoperative Vomiting</condition>
  <condition>Opioid Use</condition>
  <arm_group>
    <arm_group_label>Opioid liberal group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Opioid free group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine Hydrochloride [Dexdor]</intervention_name>
    <description>Initial dosis of dexmedetomidine 1 mcg/kg IBW iv will be administered within 10 minutes before general anesthesia induction. Following intubation infusion of 1 mcg/kg IBW / h will be initiated and continued until the end of operation.</description>
    <arm_group_label>Opioid free group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil [Ultiva]</intervention_name>
    <description>Remifentanil TCI Minto Model will be used during induction in dosis 6 ng/ml and intraoperatively appropriately to maintain hemodynamical stability.</description>
    <arm_group_label>Opioid liberal group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine [Ketalar]</intervention_name>
    <description>Ketamine 0,5mg/kg IBW iv will be administered during induction of general anesthesia.</description>
    <arm_group_label>Opioid free group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine [Xylocaine 2%]</intervention_name>
    <description>Initial dosis of lidocaine 1,5 mg/kg IBW iv will be administered within 10 minutes before general anesthesia induction. Following intubation infusion of 3 mg/kg IBW / h will be initiated and continued until the end of operation.</description>
    <arm_group_label>Opioid free group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulphate [Inj. Magnesii Sulfurici Polpharma]</intervention_name>
    <description>Magnesium Sulphate will be administered in dosis 50 mg/kg IBW iv intraoperatively.</description>
    <arm_group_label>Opioid free group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl [Fentanyl WZF]</intervention_name>
    <description>Rescue dosis of 100 mcg iv will be administered if hypertension &gt; 140/90 mmHg or tachycardia &gt; 120min occurs. If necessary rescue dosis may be repeated.</description>
    <arm_group_label>Opioid free group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sleeve gastrectomy in patients with BMI &gt; 40 or &gt;35 with comorbidities

          -  Written informed consent

        Exclusion Criteria:

          -  Patient's refusal

          -  Known allergies to study medication

          -  Inability to comprehend or participate In pain scoring scale

          -  Inability to use intravenous patient controlled analgesia

          -  Changes of operation extent during procedure

          -  Revisional operations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piotr Mieszczański, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Warsaw</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Piotr Mieszczański, MD</last_name>
    <phone>+48669643205</phone>
    <email>piotr.mieszczanski@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Szpital Kliniczny Dzieciatka Jezus</name>
      <address>
        <city>Warsaw</city>
        <zip>02-005</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Mieszczanski</last_name>
      <phone>+48669643205</phone>
      <email>piotr.mieszczanski@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 29, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opioid free anesthesia</keyword>
  <keyword>Laparoscopic sleeve gastrectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Magnesium Sulfate</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

